We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mitigating risk in academic preclinical drug discovery.
- Authors
Dahlin, Jayme L.; Inglese, James; Walters, Michael A.
- Abstract
The number of academic drug discovery centres has grown considerably in recent years, providing new opportunities to couple the curiosity-driven research culture in academia with rigorous preclinical drug discovery practices used in industry. To fully realize the potential of these opportunities, it is important that academic researchers understand the risks inherent in preclinical drug discovery, and that translational research programmes are effectively organized and supported at an institutional level. In this article, we discuss strategies to mitigate risks in several key aspects of preclinical drug discovery at academic drug discovery centres, including organization, target selection, assay design, medicinal chemistry and preclinical pharmacology.
- Subjects
PHARMACOLOGY; PHARMACEUTICAL chemistry; DRUG synthesis; DRUG development; CLINICAL trials
- Publication
Nature Reviews Drug Discovery, 2015, Vol 14, Issue 4, p279
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd4578